Latest International Expansion News

Page 4 of 56
Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
Victor Sage
Victor Sage
29 Sept 2026
Viva Leisure used FY2026 to prove its existing club network could generate stronger returns without rapid expansion, lifting revenue 12.2% and underlying NPAT 46.4%. The ASX-listed fitness group is now preparing to accelerate openings while reviewing options for its faster-growing payments and technology business.
Victor Sage
Victor Sage
29 Sept 2026
Rubicon Water’s technology has been selected as part of a joint venture bid for a major Moroccan irrigation upgrade covering 69,600 hectares. The opportunity could become its largest EMEA contract, but formal execution remains subject to a 15-day appeal period and subsequent commissioning.
Victor Sage
Victor Sage
28 Sept 2026
SkinKandy Limited (ASX:SK1) exceeded its IPO forecasts in FY26, with pro forma revenue rising 29% to A$90.2 million and pro forma NPAT climbing 41% to A$9.0 million. The newly listed retailer enters FY27 with 115 stores, 11 approved leases and plans for potential expansion into South Africa and the United States.
Victor Sage
Victor Sage
25 Sept 2026
Me Today reported a NZ$2.66 million FY26 profit, but the result was dominated by a NZ$4.12 million gain from losing control of King Honey. The remaining business grew revenue and improved its operating loss, yet continued to consume cash and will rely on October warrant funding.
Victor Sage
Victor Sage
25 Sept 2026
Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.
Sophie Babbage
Sophie Babbage
24 Sept 2026
Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.
Ada Torres
Ada Torres
22 Sept 2026
Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.
Ada Torres
Ada Torres
22 Sept 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Klevo Group Limited (ASX:KLV) has announced a pro-rata entitlement issue of Loyalty Options to raise approximately $3.1 million, aiming to accelerate its credit capabilities and expand its Mastercard program in Asia.
Sophie Babbage
Sophie Babbage
4 Sept 2026
Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.
Victor Sage
Victor Sage
31 Aug 2026

Browse the archive

Full archive